Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Progenics Pharmaceuticals Inc (PGNX) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Progenics Pharmaceuticals Inc. (See page 1 of this report.) Table 2 shows the detailed insider transactions. The reporting company's CIK number is 835887.
Total stock buying since 2005: $11,893,679.
Total stock sales since 2005: $30,175,090.
Total stock option exercises since 2005: $9,421,383.
▪ Recent SEC 13D filings for PGNX
▪ Recent SEC 13D filings for all companies
▪ Funds & ETFs holding PGNX
▪ Recent portfolio reports of all companies
A schedule 13D must be filed with the SEC when a person or group of persons acquires beneficial ownership of more than 5% of Progenics Pharmaceuticals Inc (PGNX). A schedule 13D/A is an amendment that is filed when there are any material changes in beneficial ownership.
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2019-09 | 658,061 | $2,984,404 | 0 | $0 | 0 | $0 |
| 2019-08 | 204,056 | $878,618 | 0 | $0 | 0 | $0 |
| 2019-07 | 0 | $0 | 0 | $0 | 22,000 | $111,979 |
| 2019-06 | 0 | $0 | 0 | $0 | 50,000 | $267,000 |
| 2017-02 | 0 | $0 | 953,900 | $9,227,413 | 0 | $0 |
| 2015-06 | 0 | $0 | 2,000 | $13,660 | 2,000 | $10,660 |
| 2015-03 | 0 | $0 | 10,000 | $67,110 | 10,000 | $50,209 |
| 2015-01 | 0 | $0 | 2,000 | $14,112 | 2,000 | $10,660 |
| 2014-12 | 0 | $0 | 3,000 | $21,201 | 3,000 | $16,049 |
| 2014-11 | 0 | $0 | 24,000 | $163,950 | 24,000 | $126,600 |
| 2014-07 | 1,625,436 | $7,476,167 | 0 | $0 | 0 | $0 |
| 2013-07 | 0 | $0 | 5,000 | $31,650 | 5,000 | $26,650 |
| 2013-03 | 650 | $3,469 | 0 | $0 | 2,500 | $9,097 |
| 2013-01 | 1,215 | $3,432 | 0 | $0 | 0 | $0 |
| 2012-12 | 1,142 | $3,437 | 0 | $0 | 0 | $0 |
| 2012-11 | 112,033 | $199,577 | 0 | $0 | 0 | $0 |
| 2012-10 | 1,162 | $3,433 | 0 | $0 | 0 | $0 |
| 2012-09 | 1,036 | $3,439 | 0 | $0 | 0 | $0 |
| 2012-08 | 815 | $3,450 | 0 | $0 | 0 | $0 |
| 2012-07 | 346 | $3,472 | 1,000 | $9,790 | 1,000 | $5,330 |
| 2012-06 | 375 | $3,474 | 1,000 | $8,508 | 1,000 | $5,330 |
| 2012-05 | 445 | $3,475 | 1,000 | $10,927 | 1,000 | $5,330 |
| 2012-04 | 348 | $3,514 | 1,000 | $9,852 | 1,000 | $5,330 |
| 2012-03 | 343 | $3,472 | 1,000 | $9,817 | 1,000 | $5,330 |
| 2012-02 | 369 | $3,484 | 35,250 | $359,205 | 2,250 | $13,955 |
| 2012-01 | 755 | $6,924 | 1,000 | $8,780 | 1,000 | $5,330 |
| 2011-12 | 0 | $0 | 1,000 | $6,660 | 1,000 | $5,330 |
| 2011-11 | 0 | $0 | 1,634 | $9,785 | 1,000 | $5,330 |
| 2011-10 | 532 | $3,467 | 1,000 | $6,330 | 15,104 | $70,545 |
| 2011-09 | 542 | $3,460 | 1,000 | $6,329 | 1,000 | $5,329 |
| 2011-08 | 571 | $3,471 | 1,000 | $6,330 | 1,000 | $5,330 |
| 2011-07 | 567 | $3,471 | 1,000 | $7,205 | 42,968 | $233,998 |
| 2011-06 | 490 | $3,469 | 14,761 | $106,382 | 1,000 | $5,330 |
| 2011-05 | 486 | $3,465 | 21,000 | $172,290 | 1,000 | $5,330 |
| 2011-04 | 479 | $3,467 | 1,000 | $6,330 | 13,222 | $67,376 |
| 2011-03 | 0 | $0 | 1,000 | $6,330 | 33,500 | $48,555 |
| 2011-02 | 0 | $0 | 7,597 | $48,089 | 7,597 | $40,492 |
| 2011-01 | 0 | $0 | 403 | $2,550 | 13,702 | $66,353 |
| 2010-12 | 5,000 | $24,500 | 0 | $0 | 0 | $0 |
| 2010-11 | 5,000 | $23,800 | 0 | $0 | 0 | $0 |
| 2010-10 | 5,000 | $24,950 | 0 | $0 | 41,475 | $179,086 |
| 2010-09 | 5,000 | $20,500 | 0 | $0 | 0 | $0 |
| 2010-08 | 5,000 | $23,750 | 0 | $0 | 0 | $0 |
| 2010-07 | 5,000 | $24,925 | 0 | $0 | 16,056 | $71,288 |
| 2010-06 | 5,000 | $24,950 | 17,281 | $101,687 | 0 | $0 |
| 2010-05 | 5,000 | $24,550 | 0 | $0 | 0 | $0 |
| 2010-04 | 0 | $0 | 0 | $0 | 20,792 | $94,726 |
| 2010-03 | 0 | $0 | 9,221 | $49,429 | 0 | $0 |
| 2010-01 | 0 | $0 | 0 | $0 | 18,226 | $68,947 |
| 2009-10 | 18,500 | $90,243 | 0 | $0 | 15,442 | $65,765 |
| 2009-07 | 0 | $0 | 0 | $0 | 43,354 | $231,075 |
| 2009-06 | 0 | $0 | 9,500 | $47,548 | 0 | $0 |
| 2009-04 | 0 | $0 | 0 | $0 | 12,279 | $69,376 |
| 2009-01 | 0 | $0 | 0 | $0 | 7,849 | $71,660 |
| 2008-10 | 0 | $0 | 62,500 | $577,625 | 37,563 | $245,280 |
| 2008-09 | 0 | $0 | 1,000 | $15,000 | 1,000 | $12,290 |
| 2008-08 | 0 | $0 | 1,000 | $16,465 | 51,000 | $493,540 |
| 2008-07 | 0 | $0 | 11,000 | $175,942 | 27,040 | $298,518 |
| 2008-06 | 0 | $0 | 1,000 | $16,397 | 1,000 | $12,290 |
| 2008-05 | 0 | $0 | 1,000 | $15,000 | 8,500 | $52,512 |
| 2008-04 | 0 | $0 | 1,000 | $15,000 | 14,792 | $102,212 |
| 2008-03 | 0 | $0 | 1,000 | $15,300 | 8,500 | $47,247 |
| 2008-02 | 0 | $0 | 1,000 | $16,440 | 1,000 | $12,290 |
| 2008-01 | 0 | $0 | 1,000 | $18,120 | 5,986 | $88,793 |
| 2007-12 | 0 | $0 | 6,000 | $115,351 | 6,000 | $42,040 |
| 2007-10 | 0 | $0 | 27,000 | $616,692 | 49,797 | $646,256 |
| 2007-09 | 0 | $0 | 24,000 | $565,908 | 24,000 | $127,920 |
| 2007-08 | 0 | $0 | 26,000 | $578,410 | 26,000 | $158,734 |
| 2007-07 | 0 | $0 | 26,000 | $560,601 | 36,536 | $422,852 |
| 2007-06 | 0 | $0 | 14,000 | $305,066 | 14,000 | $94,774 |
| 2007-05 | 0 | $0 | 26,000 | $613,960 | 26,000 | $158,734 |
| 2007-04 | 0 | $0 | 30,000 | $769,362 | 34,393 | $384,612 |
| 2007-03 | 0 | $0 | 36,000 | $898,714 | 36,000 | $198,734 |
| 2007-02 | 0 | $0 | 62,000 | $1,858,002 | 62,000 | $332,680 |
| 2007-01 | 0 | $0 | 38,500 | $1,062,826 | 51,232 | $478,080 |
| 2006-12 | 0 | $0 | 50,000 | $1,344,807 | 50,000 | $258,300 |
| 2006-11 | 0 | $0 | 52,000 | $1,433,356 | 52,000 | $262,734 |
| 2006-10 | 0 | $0 | 33,000 | $789,341 | 38,192 | $371,915 |
| 2006-09 | 0 | $0 | 29,000 | $672,728 | 29,000 | $147,920 |
| 2006-08 | 0 | $0 | 29,000 | $609,252 | 29,000 | $147,920 |
| 2006-07 | 0 | $0 | 29,000 | $658,453 | 43,904 | $532,616 |
| 2006-06 | 0 | $0 | 37,025 | $803,159 | 15,000 | $73,300 |
| 2006-05 | 0 | $0 | 39,000 | $897,840 | 39,000 | $182,600 |
| 2006-04 | 0 | $0 | 25,000 | $639,440 | 29,231 | $271,170 |
| 2006-03 | 0 | $0 | 32,000 | $905,380 | 32,000 | $154,600 |
| 2006-02 | 0 | $0 | 50,500 | $1,407,893 | 49,000 | $318,850 |
| 2006-01 | 0 | $0 | 8,000 | $221,064 | 12,528 | $203,010 |
| 2005-09 | 0 | $0 | 5,000 | $125,000 | 0 | $0 |
| 2005-06 | 0 | $0 | 15,150 | $301,947 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2010-06-22 | Olson William C (VP, Research & Development) | Sale | 2,364 | 5.80 | 13,723 |
| 2010-06-22 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 6,180 | 5.82 | 35,961 |
| 2010-06-18 | Mckinney Robert A (Chief Financial Officer) | Sale | 4,000 | 6.25 | 25,000 |
| 2010-06-01 | Maddon Paul J (Chief Executive Officer/CSO) | Buy | 5,000 | 4.99 | 24,950 |
| 2010-05-20 | Maddon Paul J (Chief Executive Officer/CSO) | Buy | 5,000 | 4.91 | 24,550 |
| 2010-04-01 | Baker Mark Robert (President) | Option Ex | 4,300 | 4.56 | 19,590 |
| 2010-04-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 5,242 | 4.56 | 23,882 |
| 2010-04-01 | Olson William C (VP, Research & Development) | Option Ex | 2,490 | 4.56 | 11,344 |
| 2010-04-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 2,621 | 4.56 | 11,941 |
| 2010-04-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 3,518 | 4.56 | 16,028 |
| 2010-03-18 | Baker Mark Robert (President) | Sale | 2,165 | 5.33 | 11,539 |
| 2010-03-18 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 7,056 | 5.37 | 37,890 |
| 2010-01-04 | Baker Mark Robert (General Counsel) | Option Ex | 4,720 | 3.78 | 17,855 |
| 2010-01-04 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 3,147 | 3.78 | 11,905 |
| 2010-01-04 | Olson William C (VP, Research & Development) | Option Ex | 2,989 | 3.78 | 11,307 |
| 2010-01-04 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 3,147 | 3.78 | 11,905 |
| 2010-01-04 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 4,223 | 3.78 | 15,975 |
| 2009-10-16 | Maddon Paul J (Chief Executive Officer/CSO) | Buy | 18,500 | 4.88 | 90,243 |
| 2009-10-01 | Baker Mark Robert (General Counsel) | Option Ex | 3,999 | 4.26 | 17,031 |
| 2009-10-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,666 | 4.26 | 11,354 |
| 2009-10-01 | Olson William C (VP, Research & Development) | Option Ex | 2,533 | 4.26 | 10,788 |
| 2009-10-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 2,666 | 4.26 | 11,354 |
| 2009-10-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 3,578 | 4.26 | 15,238 |
| 2009-07-01 | Baker Mark Robert (General Counsel) | Option Ex | 13,207 | 5.33 | 70,393 |
| 2009-07-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 7,738 | 5.33 | 41,243 |
| 2009-07-01 | Olson William C (VP, Research & Development) | Option Ex | 6,461 | 5.33 | 34,437 |
| 2009-07-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 7,738 | 5.33 | 41,243 |
| 2009-07-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 8,210 | 5.33 | 43,759 |
| 2009-06-23 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 4.73 | 9,468 |
| 2009-06-23 | Olson William C (VP, Research & Development) | Sale | 2,500 | 4.73 | 11,815 |
| 2009-06-19 | Mckinney Robert A (Chief Financial Officer) | Sale | 5,000 | 5.25 | 26,265 |
| 2009-04-01 | Baker Mark Robert (General Counsel) | Option Ex | 3,180 | 5.65 | 17,967 |
| 2009-04-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,120 | 5.65 | 11,978 |
| 2009-04-01 | Olson William C (VP, Research & Development) | Option Ex | 2,014 | 5.65 | 11,379 |
| 2009-04-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 2,120 | 5.65 | 11,978 |
| 2009-04-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 2,845 | 5.65 | 16,074 |
| 2009-01-02 | Baker Mark Robert (General Counsel) | Option Ex | 2,033 | 9.13 | 18,561 |
| 2009-01-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 1,355 | 9.13 | 12,371 |
| 2009-01-02 | Olson William C (VP, Research & Development) | Option Ex | 1,287 | 9.13 | 11,750 |
| 2009-01-02 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 1,355 | 9.13 | 12,371 |
| 2009-01-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,819 | 9.13 | 16,607 |
| 2008-10-23 | Jacobson Paul F (Director) | Sale | 27,000 | 9.05 | 244,458 |
| 2008-10-22 | Jacobson Paul F (Director) | Sale | 35,500 | 9.38 | 333,167 |
| 2008-10-01 | Baker Mark Robert (General Counsel) | Option Ex | 4,786 | 6.53 | 31,252 |
| 2008-10-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 8,768 | 6.53 | 57,254 |
| 2008-10-01 | Olson William C (VP, Research & Development) | Option Ex | 2,968 | 6.53 | 19,380 |
| 2008-10-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 3,638 | 6.53 | 23,756 |
| 2008-10-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 4,882 | 6.53 | 31,878 |
| 2008-09-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-09-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-08-28 | Briner Kurt W (Director) | Option Ex | 50,000 | 9.62 | 481,250 |
| 2008-08-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.46 | 16,465 |
| 2008-08-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-07-15 | Jacobson Paul F (Director) | Sale | 10,000 | 16.04 | 160,350 |
| 2008-07-15 | Jacobson Paul F (Director) | Option Ex | 10,000 | 6.88 | 68,820 |
| 2008-07-01 | Baker Mark Robert (General Counsel) | Option Ex | 4,865 | 13.64 | 66,358 |
| 2008-07-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,921 | 13.64 | 39,842 |
| 2008-07-01 | Olson William C (VP, Research & Development) | Option Ex | 2,296 | 13.64 | 31,317 |
| 2008-07-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 2,921 | 13.64 | 39,842 |
| 2008-07-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.59 | 15,592 |
| 2008-07-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 4,037 | 12.96 | 52,339 |
| 2008-06-02 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.40 | 16,397 |
| 2008-06-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-05-27 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-05-27 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-05-14 | Dalton Mark F (Director) | Option Ex | 7,500 | 5.36 | 40,222 |
| 2008-04-25 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.00 | 15,000 |
| 2008-04-25 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-04-01 | Baker Mark Robert (General Counsel) | Option Ex | 2,533 | 6.52 | 16,515 |
| 2008-04-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 1,914 | 6.52 | 12,479 |
| 2008-04-01 | Kremer Alton B (VP, Clinical Research) | Option Ex | 3,153 | 6.52 | 20,557 |
| 2008-04-01 | Olson William C (VP, Research & Development) | Option Ex | 1,576 | 6.52 | 10,275 |
| 2008-04-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 1,914 | 6.52 | 12,479 |
| 2008-04-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 2,702 | 6.52 | 17,617 |
| 2008-03-28 | Scheinberg David A (Director) | Option Ex | 7,500 | 4.66 | 34,957 |
| 2008-03-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 15.30 | 15,300 |
| 2008-03-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-02-01 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 16.44 | 16,440 |
| 2008-02-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2008-01-02 | Baker Mark Robert (General Counsel) | Option Ex | 916 | 15.33 | 14,042 |
| 2008-01-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 692 | 15.33 | 10,608 |
| 2008-01-02 | Kremer Alton B (VP, Clinical Research) | Option Ex | 1,139 | 15.36 | 17,495 |
| 2008-01-02 | Olson William C (VP, Research & Development) | Option Ex | 570 | 15.33 | 8,738 |
| 2008-01-02 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 692 | 15.33 | 10,608 |
| 2008-01-02 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 18.12 | 18,120 |
| 2008-01-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,977 | 13.81 | 27,302 |
| 2007-12-06 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 20.00 | 20,000 |
| 2007-12-06 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 13.75 | 13,750 |
| 2007-12-03 | Olson William C (VP, Research & Development) | Sale | 4,000 | 19.03 | 76,112 |
| 2007-12-03 | Olson William C (VP, Research & Development) | Option Ex | 4,000 | 4.00 | 16,000 |
| 2007-12-03 | Israel Robert J (Sr. VP, Medical Affairs) | Sale | 1,000 | 19.24 | 19,239 |
| 2007-12-03 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,000 | 12.29 | 12,290 |
| 2007-10-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 15,000 | 23.49 | 352,380 |
| 2007-10-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 15,000 | 5.33 | 79,950 |
| 2007-10-01 | Baker Mark Robert (General Counsel) | Option Ex | 1,496 | 19.03 | 28,468 |
| 2007-10-01 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 4,058 | 19.03 | 77,222 |
| 2007-10-01 | Kremer Alton B (VP, Clinical Research) | Option Ex | 4,656 | 19.03 | 88,602 |
| 2007-10-01 | Olson William C (VP, Research & Development) | Option Ex | 932 | 19.03 | 17,734 |
| 2007-10-01 | Mckinney Robert A (Chief Financial Officer) | Option Ex | 1,130 | 19.03 | 21,502 |
| 2007-10-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 22.03 | 264,312 |
| 2007-10-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 13,995 | 12.18 | 170,459 |
| 2007-10-01 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 1,596 | 19.03 | 30,370 |
| 2007-09-17 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.39 | 280,728 |
| 2007-09-17 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-09-04 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.77 | 285,180 |
| 2007-09-04 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-08-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.88 | 45,766 |
| 2007-08-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,000 | 15.41 | 30,814 |
| 2007-08-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.16 | 277,860 |
| 2007-08-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-08-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.23 | 254,784 |
| 2007-08-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-07-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 21.51 | 43,018 |
| 2007-07-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,000 | 15.41 | 30,814 |
| 2007-07-16 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.46 | 257,472 |
| 2007-07-16 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-07-02 | Baker Mark Robert (General Counsel) | Option Ex | 3,451 | 18.71 | 64,568 |
| 2007-07-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 545 | 18.71 | 10,196 |
| 2007-07-02 | Kremer Alton B (VP, Clinical Research) | Option Ex | 852 | 18.71 | 15,940 |
| 2007-07-02 | Olson William C (VP, Research & Development) | Option Ex | 1,546 | 18.71 | 28,925 |
| 2007-07-02 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.68 | 260,111 |
| 2007-07-02 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 13,986 | 12.02 | 168,111 |
| 2007-07-02 | Israel Robert J (Sr. VP, Medical Affairs) | Option Ex | 2,156 | 18.71 | 40,338 |
| 2007-06-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.03 | 44,054 |
| 2007-06-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,000 | 15.41 | 30,814 |
| 2007-06-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.75 | 261,012 |
| 2007-06-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-05-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 21.90 | 43,804 |
| 2007-05-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,000 | 15.41 | 30,814 |
| 2007-05-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 21.90 | 262,800 |
| 2007-05-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-05-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 25.61 | 307,356 |
| 2007-05-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-04-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 4,000 | 26.94 | 107,748 |
| 2007-04-16 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 4,000 | 15.41 | 61,628 |
| 2007-04-16 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.80 | 321,588 |
| 2007-04-16 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-04-02 | Baker Mark Robert (General Counsel) | Option Ex | 621 | 20.13 | 12,500 |
| 2007-04-02 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,018 | 20.13 | 40,622 |
| 2007-04-02 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 23.85 | 286,152 |
| 2007-04-02 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 13,754 | 12.73 | 175,088 |
| 2007-03-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 2,000 | 22.78 | 45,568 |
| 2007-03-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Option Ex | 2,000 | 15.41 | 30,814 |
| 2007-03-15 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 22.95 | 275,424 |
| 2007-03-15 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-03-01 | Scheinberg David A (Director) | Sale | 10,000 | 25.99 | 259,890 |
| 2007-03-01 | Scheinberg David A (Director) | Option Ex | 10,000 | 4.00 | 40,000 |
| 2007-03-01 | Maddon Paul J (Chief Executive Officer/CSO) | Sale | 12,000 | 26.49 | 317,832 |
| 2007-03-01 | Maddon Paul J (Chief Executive Officer/CSO) | Option Ex | 12,000 | 5.33 | 63,960 |
| 2007-02-15 | Boyd Thomas A (Sr. VP, Product Dev.) | Sale | 4,000 | 29.97 | 119,896 |
Insider trading activities including stock purchases, stock sales, and option exercises of PGNX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Progenics Pharmaceuticals Inc (symbol PGNX, CIK number 835887) see the Securities and Exchange Commission (SEC) website.